PRVA

PRVA

USD

Privia Health Group Inc. Common Stock

$23.170-0.100 (-0.430%)

Reaalajas hind

Healthcare
Health Information Services
Ameerika Ühendriigid

Hinnagraafik

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$23.270

Kõrge

$23.370

Madal

$22.750

Maht

0.01M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

2.8B

Tööstusharu

Health Information Services

Riik

United States

Kauplemisstatistika

Keskmine maht

0.83M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $15.92Praegune $23.170Kõrge $26.037

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 17. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

[PRVA: Privia Health Group Inc. Common Stock]: Analyst Buzz & Stock Moves - What's the Story?

Stock Symbol: PRVA Generate Date: 2025-04-17 01:36:19

Alright, let's take a look at Privia Health Group (PRVA). It's a company in the healthcare sector, specifically in health information services. Think of them as helping doctors' offices run more smoothly and efficiently. Recent news and stock price action are giving us some interesting signals.

Recent News Buzz: Analysts are (Mostly) Still Fans

What's the vibe around PRVA in the news? Well, it's generally positive, which is always good to see. We've got a few analyst updates, and the overall message is that these experts still see potential in the stock.

Specifically, Baird just reiterated an "Outperform" rating – that's like saying they think it'll do better than the average stock – and even bumped up their price target to $26. Barclays is a bit more neutral with an "Equal-Weight" rating, but they also raised their price target, to $23. Truist Securities is sticking with a "Buy" rating, though they nudged their price target down a bit to $28. Finally, Needham is firmly in the "Buy" camp, keeping their price target at a solid $30.

So, what does this mean? Basically, the people who spend their days analyzing stocks are still mostly positive on Privia Health. They think the stock price could go up, with targets ranging from $23 to $30. It's not a unanimous cheer, but definitely leaning optimistic.

Price Check: A Bit of a Rollercoaster Lately

Now, let's peek at what the stock price has actually been doing. Looking back over the last month or so, it's been a bit of a bumpy ride. If you glance at the numbers, you'll see a period in early February where the price was climbing, hitting highs around $25. Then, things cooled off, and it drifted downwards through much of March, hitting lows in the $21-$22 range in early April.

However, it seems like it's been trying to bounce back a bit in April. The last few trading days show the price hovering around $24. The most recent close was $24.19. So, after a dip, it's showing signs of trying to recover.

Interestingly, AI predictions suggest a small bump today and then a more noticeable climb over the next couple of days. They're forecasting a few percentage points of increase.

Outlook & Ideas: Cautiously Optimistic, But Watch Closely

Putting it all together, what's the takeaway? It feels like there's a cautiously optimistic lean for PRVA right now.

Why cautiously optimistic? The analyst news is generally positive, suggesting experts see upside. The AI predictions also point to potential near-term gains. Technically, some indicators are flashing bullish signals, like positive momentum and potential buying pressure. However, the stock price has been quite volatile recently, and some fundamental metrics (like high P/E ratio and lower growth) raise questions about valuation.

Potential Entry Consideration: If you're thinking about getting in, the current price range around $24 might be an area to watch. It's near a potential support level, and if the predicted upward trend plays out, it could be a decent entry point. But, and this is important, consider waiting for a bit of confirmation – maybe see if it holds above $24 and shows further upward momentum.

Potential Exit/Stop-Loss Consideration: On the upside, analyst price targets range up to $30. A more conservative take-profit might be around $25.70 - $26, aligning with some analyst targets and the AI's projected target price. For risk management, a stop-loss could be placed below recent lows, perhaps around $23.50 or even a bit lower, depending on your risk tolerance. This is to protect yourself if the stock decides to resume its downward trend.

Company Context Reminder: Privia Health is in the business of helping healthcare providers operate more efficiently. So, news and trends affecting the healthcare industry in general, and physician practices specifically, are extra relevant for this stock.

In short: PRVA is showing some positive signs, but it's not a slam dunk. Keep an eye on price action, watch for confirmation of the predicted upward movement, and always manage your risk. It could be an interesting short-term trading opportunity, but due diligence is key.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. I am acting as an analyst interpreting publicly available data. Investing in the stock market involves risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Seotud uudised

Analyst Upgrades

JMP Securities Reiterates Market Outperform on Privia Health Gr, Maintains $29 Price Target

JMP Securities analyst Constantine Davides reiterates Privia Health Gr with a Market Outperform and maintains $29 price target.

Vaata rohkem
JMP Securities Reiterates Market Outperform on Privia Health Gr, Maintains $29 Price Target
Analyst Upgrades

Baird Maintains Outperform on Privia Health Gr, Raises Price Target to $26

Baird analyst Michael Ha maintains Privia Health Gr with a Outperform and raises the price target from $24 to $26.

Vaata rohkem
Baird Maintains Outperform on Privia Health Gr, Raises Price Target to $26
Analyst Upgrades

Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23

Barclays analyst Andrew Mok maintains Privia Health Gr with a Equal-Weight and raises the price target from $21 to $23.

Vaata rohkem
Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $23
Analyst Upgrades

Truist Securities Maintains Buy on Privia Health Gr, Lowers Price Target to $28

Truist Securities analyst Jailendra Singh maintains Privia Health Gr with a Buy and lowers the price target from $27 to $28.

Vaata rohkem
Truist Securities Maintains Buy on Privia Health Gr, Lowers Price Target to $28
Analyst Upgrades

Needham Reiterates Buy on Privia Health Gr, Maintains $30 Price Target

Needham analyst Matthew Sheerin reiterates Privia Health Gr with a Buy and maintains $30 price target.

Vaata rohkem
Needham Reiterates Buy on Privia Health Gr, Maintains $30 Price Target

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 28. apr 2025, 14:56

LangevNeutraalneTõusev

67.5% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
Mõõdukas
Kauplemisjuhend

Sisenemispunkt

$23.19

Võta kasum

$24.59

Peata kahjum

$20.86

Põhitegurid

PDI 5.7 on MDI 4.2 kohal ADX-iga 17.7, mis viitab tõusutrendile
Praegune hind on tugitasemele ($23.15) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 5.1x keskmisest (8,635), mis viitab äärmiselt tugevale ostusurvele
MACD 0.0228 on signaalijoone 0.0279 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.